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Abstract
Introduction Various endovascular techniques can be used
to treat cerebral vasospasm after aneurysmal subarachnoid
haemorrhage (SAH) including intra-arterial administration
of vasodilator drugs such as papaverine or nicardipine and
balloon dilatation of the affected vessel segment. Papaver-
ine is known to have side effects, and we report a possible
new one.
Materials and methods After the treatment of cerebral
vasospasm in a SAH patient by intra-arterial administration
of papaverine into the left posterior cerebral artery, severe
mesencephalic extravasation of blood and contrast media
was detected.
Results After reviewing the literature, the authors conclude
that interruption of the blood–brain barrier by papaverine
most likely combined with a secondary hyperperfusion
phenomena, and perhaps a direct toxic effect on brain tissue
was the mechanism of this major complication.
Conclusion In treating vasospasm in areas with a high
density of perforating arteries, especially in the posterior
circulation, papaverine should be used cautiously because a
safe regimen has yet to be established. In this situation,
alternative agents such as calcium channel blockers could
be considered, but evidence-based data are still missing.
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Complication of treatment
Introduction
Cerebral vasospasm remains a major problem in the
subacute treatment of subarachnoid haemorrhage (SAH).
Angiographically detectable in about 70% of patients, it
leads to delayed neurological deficits in 20% to 30%, with
7% of patients dying [1]. Various endovascular techniques
were developed to treat vasospasm including intra-arterial
administration of papaverine (IAP), which was introduced
in 1992 [2–4]. Papaverine leads to an improvement of
cerebral blood flow (CBF) by dilating the proximal,
intermediate, and distal cerebral arteries [5–8]. As a result,
oxygen supply is increased, preventing further lactate brain
acidosis and facilitating recovery [9, 10].
Angiographic improvement is achieved in up to 96% and
clinical improvement in 33% to 80% [5, 10–12]. Here, we
describe a new complication of IAP.
Case presentation
A ruptured anterior communicating artery aneurysm was
clipped in a 67-year-old woman suffering SAH (Fig. 1a,b).
Seven days later, vasospasm was suspected on transcranial
duplex ultrasound. A computed tomography (CT) perfusion
scan showed changes typical of vasospasm in the left pos-
terior cerebral artery (PCA) territory (Fig. 1c,d [13–15]),
and digital subtraction angiogram confirmed vasospasm in
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the left P1 segment (Fig. 2a,b). IAP was indicated [16], and
a FastTracker 10 catheter was easily placed at the origin of
the left PCA and an initial infusion of 150 mg papaverine
(diluted to 0.3%) made over 25 min without improvement
in the vessel diameter (Fig. 2c). Therefore, another 150 mg
papaverine was administered, and the vasospasm relieved
(Fig. 2d).
Following the infusion, the left pupil was found to have
dilatated, though intracranial pressure (ICP) remained
normal. An immediate brain CT showed a new lesion in
the left mesencephalon without significant mass effect or
crossing of the midline (Fig. 3).
The patient was referred to the intensive care unit. As
vasospasm worsened, hypothermia and barbiturate coma
were initiated [17], but no further endovascular interven-
tions were undertaken. Follow-up CT scans showed
progressive infarctions, and resolution of the mesencephalic
hyperdensity resolved. The patient died on day 25.
Fig. 1 a CT on admission, showing excessive SAH (Fisher grade 3,
Hunt &Hess grade 5). b Aneurysm of the anterior communicating artery
detected in computed tomography angiography. c, d CT perfusion:
Prolonged time to peak (c) and normal cerebral blood volume (d) in the
left PCA territory, while CBF was slightly decreased without new
infarctions in cranial computed tomography (data not shown)
Fig. 2 a Initial angiogram showing normal vessel diameters. b
Vasospasm of the left P1 segment before IAP. c Control after
administration of 150 mg of papaverine showing no relevant change
in the vessel caliber. d Final angiographic control after administration
of a total of 300 mg showing no hints for a vessel rupture
Fig. 3 Immediately after IAP, a new hyperdense lesion is noted in the
left mesencephalon without crossing of the midline (b, c, d) when
compared to the CT before the procedure (a). Note the absence of a
significant mass effect as one would expect in the case of hemorrhage.
Furthermore, no vessel rupture or extravasation of contrast dye was
noted during the procedure. The Hounsfield units (55 to 110) of more
than 100 suggest that also part of the contrast dye contributes to the
extravasation
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Discussion
Papaverine acts directly on vascular smooth muscle cells by
inhibiting cyclic adenosine monophosphate and cyclic
guanosine 3,5 monophosphate leading to vasodilatation
[18]. We have routinely performed IAP, with good results,
since 1993 [4, 9, 16, 17, 19]. The incident reported here
with a new intraparenchymal hyperdensity without mass
effect has not been observed before.
Three mechanisms may play a role. First, evidence from
animal studies suggests that infusion of papaverine may
lead to a disruption of the blood–brain barrier (BBB) with
extravasation of blood and radiographic contrast agents
[20]. Another group noted that, in higher concentrations,
papaverine may damage luminal endothelial and smooth
muscle cells because of its high acidity [21]. Besides, high
concentrations of the drug may lead to its precipitation and
subsequent microembolization [22–24]. Second, because
IAP locally increases CBF through vasodilatation [7, 25],
hyperperfusion after treatment may facilitate extravasation
[12], especially in the presence of a damaged BBB. Third, a
direct neurotoxic effect of papaverine seems possible.
Smith et al. detected changes in the gray matter and in the
neurological status of patients after treatment with IAP.
Based on their imaging data and a pathological examina-
tion, they suggest that IAP leads to a blockade of
mitochondrial respiration and inhibition of the Krebs cycle
[26]. Considering the almost immediate effect in our case,
this mechanism does not seem to have played an important
role but may have contributed to the devastating outcome.
Although dilutions of 0.6% papaverine have been
administered in humans without complications [27], this
concentration might easily be exceeded locally in the
presence of vasospasm. A distal spastic vessel segment
may reduce the physiological dilution of papaverine, and an
accumulation of the drug in proximal perforators may cause
damage of the vessel wall [21].
Although we cannot exclude preexisting ischemia in the
affected area making the tissue more vulnerable, the
absence of clinical symptoms or hypodensities on CT
before treatment makes this unlikely (Fig. 3a), and the
findings on CT perfusion were not typical for irreversible
infarction [28]. In circumstances similar to our patient,
McAuliffe et al. reported a patient who died due to a
hemorrhage in the basal ganglia immediately after IAP in
this territory. The authors excluded vessel rupture as the
cause [29].
The dose and infusion rate of papaverine remain
unsolved, and published guidelines are lacking. In the
literature, 150 to 300 mg papaverine administered per
vessel segment seems to be a generally accepted dose [1, 3,
7, 9–11, 16, 22, 30–35]. However, reported doses vary
widely from a few milligrams [2, 5] to more than 400 mg
[26, 27, 32, 35]. For the posterior circulation, only few
cases have been published [9, 27, 32]. Furthermore,
recommended infusion rates vary substantially between 15
to 60 min for 300 mg [3, 6, 7, 22, 26, 30–34]. In our case,
either the dose (300 mg) or the rate (50 min) or both seem
to have been inappropriate. Therefore, we recommend
using less than 300 mg per segment in the posterior
circulation at even slower infusion rates than usual.
There are alternative drugs for the endovascular treat-
ment of vasospasm. Most of them are calcium channel
antagonists, e.g., nimodipine or nicardipine. But there are
only small series reported in the literature with success rates
ranging from 43% to 100% and from 29% to 89% as
measured by increase in vessel diameter and neurological
improvement, respectively. Adverse effects, such as circu-
latory events or, infrequently, ICP increase, were described
in 0% to 33% of patients [1, 36–38]. Compared to
papaverine, a direct neuroprotective effect of nimodipine
has been postulated [1], while the problem of a transient
treatment effect remains [39].
Conclusion
We assume that our case was the result of a combination of
factors in which pathological hemodynamics due to
vasospasm caused an unexpected high concentration of
papaverine in perforator vessels, leading to BBB disruption
with extravasation of blood and contrast media, possibly
facilitated by secondary hyperperfusion. Therefore, we
suggest a very cautious use of the drug especially in areas
with numerous perforators proximal to a vasospastic
segment. Safe infusion rates and dosage still need to be
established. On the other hand, further studies need to
prove the potential advantage of alternative drugs such as
calcium channel antagonists.
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